Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Dosage regimen for administering a CD19XCD3 bispecific antibody

Dosage regimen for administering a CD19XCD3 bispecific antibody

US Patent 10662243 · Granted May 26, 2020

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Antibody constructs for CDH19 and CD32025
Antibody constructs for DLL3 and CD32025
PSMA and CD3 bispecific T cell engaging antibody constructs2025
Antibody constructs for DLL3 and CD32025
Antibody constructs for CDH19 and CD32025
Cross-species-specific PSMAxCD3 bispecific single chain antibody2025
Binding molecules for BCMA and CD32025
Binding molecules for BCMA and CD32025
Nucleic acids encoding anitbody constructs binding EGFR VIII and CD32024
Cross-species-specific single domain bispecific single chain antibody2024
Compositions comprising cross-species-specific antibodies and uses thereof2024
Bispecific antibody constructs for CDH3 and CD32024